Recourse Biologics, Inc.
Recourse Biologics is a clinical-stage biotech company focused on precision immuno-oncology. The company develops first-in-class immunotherapeutics that modulate cytotoxic lymphocyte persistence, memory formation, and cytotoxicity with the objective of minimizing systemic toxicity. Its lead program is a novel immunotherapeutic currently described as 12 months from IND, and the pipeline also includes antibody-drug conjugates and a bispecific antibody platform directed at tumor-selective targets.
Industries
N/A
Nr. of Employees
small (1-50)
Products
RB101 (lead immunotherapeutic)
A first-in-class immunotherapeutic designed to increase persistence, memory formation, and cytotoxicity of professional killer cells while avoiding systemic toxicity and immune exhaustion; described as ~12 months from IND filing.
Antibody-drug conjugate (ADC) programs
Pipeline of optimized ADCs targeting novel tumor-selective antigens across multiple large-market tumor indications.
Bispecific antibody platform
Platform technology for creating bispecific constructs that redirect cytotoxic lymphocytes into the tumor microenvironment with reduced non-specific cytokine release.
RB101 (lead immunotherapeutic)
A first-in-class immunotherapeutic designed to increase persistence, memory formation, and cytotoxicity of professional killer cells while avoiding systemic toxicity and immune exhaustion; described as ~12 months from IND filing.
Antibody-drug conjugate (ADC) programs
Pipeline of optimized ADCs targeting novel tumor-selective antigens across multiple large-market tumor indications.
Bispecific antibody platform
Platform technology for creating bispecific constructs that redirect cytotoxic lymphocytes into the tumor microenvironment with reduced non-specific cytokine release.
Expertise Areas
- Immuno-oncology
- Antibody engineering and bispecific design
- Antibody-drug conjugate development
- Preclinical and IND-enabling development
Key Technologies
- Bispecific antibodies
- Antibody-drug conjugates (ADC)
- Immunotherapeutic molecules modulating cytotoxic lymphocytes
- Tumor-selective targeting
News & Updates
Company attended a conference in Boston to discuss oncology approaches and preclinical assets targeting diverse tumor indications.
Company attended a conference to discuss oncology response approaches.
Announcement that lead compound RB101 continues to show promising preclinical results and maintains a 12-month timeline to IND filing.
Company attended a conference in Boston to discuss oncology approaches and preclinical assets targeting diverse tumor indications.
Company attended a conference to discuss oncology response approaches.
Announcement that lead compound RB101 continues to show promising preclinical results and maintains a 12-month timeline to IND filing.